Setback for Alvogen in approval bid for IBS generic
District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 August 2018 Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
17 December 2015 Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.
28 August 2018 Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
17 December 2015 Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.
28 August 2018 Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
17 December 2015 Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.